AstraZeneca (ZEG) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZEG Analyst Ratings

Strong Buy

15 Buy

2 Hold

0 Sell

Based on 17 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZEG Stock 12 Month Forecast

Average Price Target

CHF173.23

▲(30.99% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is CHF173.23 with a high forecast of CHF218.60 and a low forecast of CHF129.19. The average price target represents a 30.99% change from the last price of CHF132.24.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"118":"CHF118","219":"CHF219","143.25":"CHF143.3","168.5":"CHF168.5","193.75":"CHF193.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":218.595168,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF218.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":173.22719045266666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF173.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129.18755421,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF129.19</span>\n  </div></div>","useHTML":true}}],"tickPositions":[118,143.25,168.5,193.75,219],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.882,142.2445513846154,148.60710276923078,154.96965415384616,161.33220553846155,167.69475692307694,174.05730830769232,180.41985969230768,186.7824110769231,193.14496246153846,199.50751384615387,205.87006523076923,212.23261661538461,{"y":218.595168,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.882,138.75470695789744,141.62741391579488,144.5001208736923,147.37282783158975,150.24553478948718,153.11824174738462,155.99094870528205,158.8636556631795,161.73636262107692,164.60906957897436,167.4817765368718,170.35448349476923,{"y":173.22719045266666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.882,135.36704263153845,134.85208526307693,134.33712789461538,133.82217052615385,133.3072131576923,132.79225578923078,132.27729842076923,131.7623410523077,131.24738368384615,130.73242631538463,130.21746894692308,129.70251157846155,{"y":129.18755421,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":119.074,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.074,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.074,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.074,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.074,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.727,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.727,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.727,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.727,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.799,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.363,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.706,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 72,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.882,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF218.60

Average Price TargetCHF173.23

Lowest Price TargetCHF129.19

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel Papadakis

Deutsche Bank

CHF129.19

Hold

-2.31%

Downside

Reiterated

10/14/26

Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)

Unknown Analyst

Nordea Markets

Not Ranked

Nordea Markets

CHF137.95→CHF158.86

Buy

20.13%

Upside

Upgraded

10/13/26

AstraZeneca upgraded to Buy from Sell at NordeaAstraZeneca upgraded to Buy from Sell at Nordea

James Gordon CFA

Barclays

CHF176.67

Buy

33.60%

Upside

Reiterated

10/13/26

Barclays Reaffirms Their Buy Rating on AstraZeneca (AZN)

Graham Parry

Citi

―

Buy

―

Reiterated

10/12/26

Citi Sticks to Its Buy Rating for AstraZeneca (AZN)

Justin Smith

Bernstein

CHF223.01→CHF218.6

Buy

65.30%

Upside

Reiterated

10/07/26

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

Luisa Hector

Berenberg Bank

CHF165.63

Buy

25.25%

Upside

Reiterated

10/07/26

AstraZeneca (AZN) Receives a Buy from Berenberg Bank

Michael Leuchten

Jefferies

CHF193.23

Buy

46.12%

Upside

Reiterated

10/07/26

Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)

Sachin Jain

Bank of America Securities

CHF182.16

Buy

37.75%

Upside

Reiterated

10/05/26

AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target

Trung Huynh

RBC Capital

CHF160.1

Buy

21.07%

Upside

Reiterated

09/29/26

RBC Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

CHF176.64

Buy

33.58%

Upside

Reiterated

09/29/26

J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

CHF182.45

Buy

37.97%

Upside

Reiterated

09/29/26

AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN

Colin White

UBS

CHF167.81

Buy

26.90%

Upside

Reiterated

09/16/26

UBS Sticks to Their Buy Rating for AstraZeneca (AZN)

Rajesh Kumar

HSBC

CHF151.8→CHF153.68

Hold

16.21%

Upside

Reiterated

09/10/26

AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBCAstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC

Steve Scala

TD Cowen

CHF199.72

Buy

51.03%

Upside

Reiterated

08/31/26

Steve Scala Reiterates Buy on AstraZeneca Citing Above-Peer EPS Growth Outlook and Selective Pipeline Upside

Unknown Analyst

CICC

Not Ranked

CICC

CHF164.77

Buy

24.60%

Upside

Initiated

08/24/26

AstraZeneca initiated with an Outperform at CICCAstraZeneca initiated with an Outperform at CICC

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel Papadakis

Deutsche Bank

CHF129.19

Hold

-2.31%

Downside

Reiterated

10/14/26

Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)

Unknown Analyst

Nordea Markets

Not Ranked

Nordea Markets

CHF137.95→CHF158.86

Buy

20.13%

Upside

Upgraded

10/13/26

AstraZeneca upgraded to Buy from Sell at NordeaAstraZeneca upgraded to Buy from Sell at Nordea

James Gordon CFA

Barclays

CHF176.67

Buy

33.60%

Upside

Reiterated

10/13/26

Barclays Reaffirms Their Buy Rating on AstraZeneca (AZN)

Graham Parry

Citi

―

Buy

―

Reiterated

10/12/26

Citi Sticks to Its Buy Rating for AstraZeneca (AZN)

Justin Smith

Bernstein

CHF223.01→CHF218.6

Buy

65.30%

Upside

Reiterated

10/07/26

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

Luisa Hector

Berenberg Bank

CHF165.63

Buy

25.25%

Upside

Reiterated

10/07/26

AstraZeneca (AZN) Receives a Buy from Berenberg Bank

Michael Leuchten

Jefferies

CHF193.23

Buy

46.12%

Upside

Reiterated

10/07/26

Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)

Sachin Jain

Bank of America Securities

CHF182.16

Buy

37.75%

Upside

Reiterated

10/05/26

AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target

Trung Huynh

RBC Capital

CHF160.1

Buy

21.07%

Upside

Reiterated

09/29/26

RBC Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

CHF176.64

Buy

33.58%

Upside

Reiterated

09/29/26

J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

CHF182.45

Buy

37.97%

Upside

Reiterated

09/29/26

AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN

Colin White

UBS

CHF167.81

Buy

26.90%

Upside

Reiterated

09/16/26

UBS Sticks to Their Buy Rating for AstraZeneca (AZN)

Rajesh Kumar

HSBC

CHF151.8→CHF153.68

Hold

16.21%

Upside

Reiterated

09/10/26

AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBCAstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC

Steve Scala

TD Cowen

CHF199.72

Buy

51.03%

Upside

Reiterated

08/31/26

Steve Scala Reiterates Buy on AstraZeneca Citing Above-Peer EPS Growth Outlook and Selective Pipeline Upside

Unknown Analyst

CICC

Not Ranked

CICC

CHF164.77

Buy

24.60%

Upside

Initiated

08/24/26

AstraZeneca initiated with an Outperform at CICCAstraZeneca initiated with an Outperform at CICC

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

EHCEncompass Health

MDWDMediwound

OVIDOvid Therapeutics

ARDXArdelyx

STOKStoke Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months

Luisa HectorBerenberg Bank

Success Rate

31/53 ratings generated profit

Average Return

+2.49%

Copying Luisa Hector's trades and holding each position for 3 Months would result in 58.49% of your transactions generating a profit, with an average return of +2.49% per trade.

1 Year

Luisa HectorBerenberg Bank

Success Rate

36/53 ratings generated profit

Average Return

+10.21%

Copying Luisa Hector's trades and holding each position for 1 Year would result in 67.92% of your transactions generating a profit, with an average return of +10.21% per trade.

2 Years

Luisa HectorBerenberg Bank

Success Rate

41/53 ratings generated profit

Average Return

+17.44%

Copying Luisa Hector's trades and holding each position for 2 Years would result in 77.36% of your transactions generating a profit, with an average return of +17.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZEG Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZEG has received 51 Buy Ratings, 4 Hold Ratings, and 5 Sell Ratings. ZEG average Analyst price target in the past 3 months is 173.23.

Each month's total comprises the sum of three months' worth of ratings.

ZEG Financial Forecast

ZEG Earnings Forecast

Next quarter’s earnings estimate for ZEG is CHF2.17 with a range of CHF2.06 to CHF2.26. The previous quarter’s EPS was CHF2.19. ZEG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.

ZEG Sales Forecast

Next quarter’s sales forecast for ZEG is CHF13.35B with a range of CHF13.13B to CHF13.58B. The previous quarter’s sales results were CHF12.66B. ZEG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.

ZEG Stock Forecast FAQ

What is CH:ZEG’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 173.23.

What is CH:ZEG’s upside potential, based on the analysts’ average price target?

AstraZeneca PLC has 30.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AstraZeneca PLC a Buy, Sell or Hold?

AstraZeneca PLC has a consensus rating of Strong Buy, which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.

What is AstraZeneca PLC’s share price target?

The average share price target for AstraZeneca PLC is 173.23. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF218.60 ,and the lowest forecast is CHF129.19. The average share price target represents 30.99% Increase from the current price of CHF132.24.

What do analysts say about AstraZeneca PLC?

AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of AstraZeneca PLC?

To buy shares of CH:ZEG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AstraZeneca (ZEG) Stock Forecast & Price Target

ZEG Analyst Ratings

ZEG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

ZEG Analyst Recommendation Trends

ZEG Financial Forecast

ZEG Earnings Forecast

ZEG Sales Forecast

ZEG Stock Forecast FAQ

Detailed List of Analyst Forecasts